

MICRO-X \$16.5M PRIVATE PLACEMENT

Funding for Nano commercialisation, launch of Rover and MBI development

Adelaide, Australia, 19 November 2019: Australian high-tech company Micro-X Ltd (ASX: MX1) (**Micro-X** or the **Company**) a leader in cold cathode x-ray technology for health and security markets globally, is pleased to announce that it has received commitments totalling approximately \$16.5 million (**Placement**), for new fully paid ordinary shares in the Company at 20 cents per share (**Placement Shares**).

The Placement was targeted to raise \$12 million to \$15 million and the Company reserved the right to accept oversubscriptions in the Placement. As the Placement was well oversubscribed the Company increased the Placement by 10% to \$16.5 million. The Company is pleased to welcome a number of new institutional and sophisticated investors as shareholders in addition to the support of a number of existing shareholders. Two of the Directors have also committed to subscribe for \$0.35 million of Placement Shares, with the allotment to Directors being subject to shareholder approval.

The Company intends to use the proceeds of the Placement to fund the ongoing commercialisation of the Nano product and the launch of the Rover for the military market targeted for 2020 with associated capex and inventory. Additionally, proceeds will be applied towards engineering development of the MBI product, working capital and costs associated with the Placement. Approximately \$2.81 million of the proceeds will be applied towards redemption of the April 2018 Convertible Notes.

The Company Presentation used in marketing for the Placement is *attached*.

Morgans Corporate was engaged as Lead Manager for the Placement with Hawkesbury Partners as Co-Arranger and Financial Advisor.

Details of the Placement

The key terms of the Placement are as follows:

- Approximately 82.5 million Placement Shares at \$0.20 per Placement Share to raise approximately \$16.5 million.
- The issue price of the Placement Shares represents a:
 - 25.0% discount to the last traded price of 25 cents on 1 November 2019; and
 - 24.8% discount to the 5-day volume weighted average price (**VWAP**), 29.3% discount to the 15-day VWAP immediately prior to the date of the Placement.
- The Placement will take place in two tranches with:
 - approximately 12.4 million Placement shares (approximately \$2.5 million) to be issued under the remainder of the Company's 15% placement capacity under ASX Listing Rule 7.1, which will be issued on or about Monday 25 November 2019; and
 - approximately 70.1 million Placement shares (approximately \$14.0 million) to be issued subject to shareholder approval.
- Two of the Company's Directors have subscribed in the Placement, for a total of 1.75 million Placement Shares (\$0.35 million), which subscriptions are also subject to shareholder approval. These shares will fall into tranche two of the Placement.
- A majority of the holders of convertible notes issued in April 2018 (**April 2018 Notes**) have subscribed for a total of approximately 28.1 million Placement Shares (approximately \$5.6 million), with each holder subscribing for

Placement Shares equal to 200% of the face value of their Notes. The Placement, once approved by shareholders, will satisfy the requirement of a Future Capital Raising under the terms of the April 2018 Notes. Accordingly, the Company will effect a redemption of approximately \$2.8 million of Notes on closing the Placement. These Placement Shares will fall into tranche two of the Placement.

- Shareholder approval will be sought at an Extraordinary General Meeting that is scheduled to take place on or about 19 December 2019. The approval by shareholders of the convertible security issued to Thales in July 2019 pursuant to the Thales Loan Agreement (details of which were disclosed to the market on 15 November 2019), will also be sought at the same Extraordinary General Meeting.
- The Placement was available to investors in Australia who qualified as professional or sophisticated investors under the requirements of the Corporations Act 2001 (Cth) and sophisticated and professional investors in select other jurisdictions. Placement Shares will rank equally with existing ordinary shares of the Company.
- As the Company's shares have been suspended from trading on the ASX for more than 5 days in the last 12 months, a transaction specific Prospectus will be lodged with the ASX and ASIC on or about 19 November 2019, being a date prior to the proposed allotment of the first tranche of Placement Shares.

Peter Rowland, Managing Director of Micro-X commented:

"We are very pleased to have attracted this level of investor commitments and the number of new shareholders joining the share register is particularly pleasing as we transition into our next phase of ramping up commercialisation. This funding allows us to execute on our exciting plans without the need to be raising again in the short term. We have also tidied up our balance sheet with the redemption of almost all of the April 2018 Notes and the recently announced repayment of the \$3 million secured R&D Loan.

Our focus is on commercial achievements and the funds raised will allow us to push ahead with our Nano roll-out and deliver meaningful levels of sales in the coming year. We are also able to progress towards completing the first generation version of the Rover and attracting two key military customers within the next twelve months. We can also fully support our engagement with Thales on the MBI and future airport screening products"

Key dates

The key dates related to the Placement are as follows:

19 November 2019	Placement announced Transaction specific Prospectus lodged with ASX and ASIC Notice of Extraordinary General Meeting lodged with ASX
25 November 2019	First tranche of Placement Shares allotted
19 December 2019	Extraordinary General Meeting to approve Placement and Thales convertible security
23 December 2019	Second tranche of Placement Shares allotted Redemption of April 2018 Notes held by holders who satisfied the redemption condition

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold

commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for airport security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com

MICRO-X Ltd

ACN 153 273 735

ASX: MX1

Company Presentation

Building sales of next generation x-ray

15th November 2019

Peter Rowland
Managing Director & CEO

SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

Overview

MICRO-X

Next generation X-ray for global health and security markets

- ASX listed **hi-tech X-ray company** based in Tonsley, Adelaide
- **Next generation, cold cathode, Carbon Nano Tube technology**
 - X-ray products with significant reduction in size, weight and power
- **Platform technology** – health and new security applications
- **Selling first product - Carestream DRX Revolution Nano**
 - Mobile ultra-lightweight digital x-ray system for hospitals
 - Sold into 10 countries including United States – Available for sale in Australia
- **Strategic partnerships and investors**
 - Distribution of Nano - Carestream (ex Kodak Medical, US\$2.5b sales)
 - Security collaboration - Thales (technology giant, €16b sales)
- **Growth trajectory - building customer traction and sales**
 - Accelerated sales and marketing activities + sales infrastructure
 - Second product - Rover product for military market – first contract for sale 1H 2020



Carestream DRX Revolution Nano

Next generation X-ray technology

MICRO-X

Our carbon nanotube technology provides a revolution in X-ray products & functions

Existing X-Ray Technology



Filament

Technology **unchanged since 1896**

Hot filament generates X-ray beam


X-ray still dominant form of diagnostic imaging

Mobile bedside X-ray – fastest growing segment

Siemens, GE, Canon, Philips, Carestream



Next Gen MICRO-X



LED

CNT emitter + electronic control generates X-ray beam

Up to 10x smaller X-ray tube

Considerably more efficient with no heat


Significant increase in functionality

New security & military applications

Product roadmap

MICRO-X

Planned product evolution – from current X-ray uses to solving unmet needs



* Additional healthcare opportunities
- e.g. Mobile 3D CT imager for stroke diagnosis

Corporate Snapshot

MICRO-X

Growth stage company with institutional and strategic investor support


Share & Trading Statistics (Closing Price on Friday 1 November 2019)

Share Price	\$0.25 per share
Total Shares On Issue	165.0 million
Options Issued	11.6 million
Convertible Notes	\$4.5 million – convert at 23 to 40 cps
Market Cap	~\$41.3 million

Key Financials & Shareholders

Current Cash	\$2.6 million (at 30 Sept 2019)
Loan Facilities	SAFA \$3 million facility
Strategic Investors	Carestream (5.7%), Thales (\$10m Con Notes)
Institutional Investors	Thorney (approx. 7%) + Other Institutions (~6%)
Board & Management	~ 10.4% shares

MX1 - Three month trading
to 1 Nov 2019



Realigned financial resources to commercial outcomes – reducing FY2020 cash expenditure by \$3.1m

Key terms of the Placement

MICRO-X

Placement	Private Placement of A\$12 – A\$15 million via a two tranche Share Placement to Institutional and Sophisticated investors at A\$0.20 per share. <ul style="list-style-type: none">Tranche 1: A\$2.48 million ~ 12.40 million sharesTranche 2: A\$9.52 million ~ 47.60 million shares up to A\$12.52 million of ~ 62.60 million shares. This second tranche of the Share Placement is subject to shareholder approval at an EGM The Company will be lodging a cleansing Prospectus with ASX and ASIC to enable shares in the Placement to be resold. The Company reserves the right to accept oversubscriptions Morgans Financial Limited have been appointed as Lead Manager. Hawkesbury Partners are Co-Arrangers and Advisers to Micro-X			
Use of proceeds	USE OF FUNDS	\$12M OFFER	\$15M OFFER	Notes
	Commercialisation on Nano; Rover work and launch*	\$3.00m	\$3.00m	Commercialisation for Nano is net of Gross Profit on Nano sales.
	MBI R&D, Capex and Inventory	\$4.40m	\$6.40m	Convertible Note Redemption is an estimate based on current indications from Note holders.
	Working Capital	\$1.32m	\$2.14m	MBI costs will be funded by proceeds from \$10m Thales facility.
	Convertible Note Redemption*	\$2.56m	\$2.56m	
	Costs of the Offer	\$0.72m	\$0.90m	
	Total	\$12.0m	\$15.0m	
Pricing	The Placement will be undertaken at a Placement Price of \$0.20 per share which represents a discount of: <ul style="list-style-type: none">24.8% to the 5-day VWAP29.3% to the 15-day VWAP20.0% to the last traded price of \$0.25 per share on 1 November 2019			
Timing^ & Settlement	Market Update Announcement	15 November 2019	EGM to approve Tranche 2	~20 December 2019
	MX1 Recommences Trading	19 November 2019	DvP Settlement of Tranche 2*	23 December 2019
	Cleansing Prospectus filed	19 November 2019	Allotment of Tranche 2 Shares*	24 December 2019
	DvP Settlement of Tranche 1	22 November 2019	* Tranche 2 is only if shareholder approval is received	
	Allotment of Tranche 1 Shares	25 November 2019	^ Dates are indicative and subject to change at the Company's discretion	
Approvals	Tranche 1 of the Placement Shares shall be issued in accordance with the Company's capacity under ASX Listing Rule 7.1 (15% rule). Tranche 2 of the Placement Shares will be issued subject to shareholder approval at an EGM to be held in December 2019			
Issued Capital	165 million ordinary shares + 11.6m options \$4.0m Convertible Notes (40c) and \$0.5m Convertible Notes (VWAP discount with 23c floor)			

Experienced leadership

MICRO-X

Technical and commercial expertise to support our goals and objectives



Peter Rowland

Managing Director & CEO

- Over 30 years' hi-tech engineering and management in military and industry
- Previously BAE Systems, Ellex Medical and Biolase Technology (NASDAQ)



Patrick O'Brien

Non-Executive Chairman


- Over 25 years' business and finance experience in UK, Asia and Australia
- Former Executive Director at Macquarie Group; McKinsey; and Minter Ellison



Yasmin King

Non-Executive Director


- Highly experienced in business, vocation and government
- Currently CEO of Skills IQ, formerly Associate Commissioner of ACCC



Dr Alexander Gosling, AM

Non-Executive Director


- Over 40 years' business, technology and research experience
- A founding Director at Invetech (Vision Systems); strategy for Capstone



Georgina Carpendale

Chief Financial Officer


10 years' experience in accounting and finance
Former Auditor at BDO



Anthony Skeets

Engineering Manager


20 years engineering experience in UK & Aust
Lucent, Invetech, Hydrix



Alexander Blackburn

Programs Manager

Highly experienced in supply chain and quality
GM Holden in Aust & China



Victoria Latham

Quality & Reg Manager

20 years Quality in medical devices and auto industry
Ellex and Carl Zeiss Vision

Global search underway to add an experienced Sales and Marketing executive to Leadership team

Commercialise our proprietary technology products with selected global partners

- **Dual Market strategy** in healthcare and defence/security – based on **proprietary technology**
 - Maintain world leading **in-house design and technology development** capabilities
 - Expand **highly robust quality manufacturing** capability
 - **Enter markets** in partnership with **globally recognised brands**
 - **First product in healthcare builds credibility** before entering **new markets without competition**
- ❖ **Earn attractive margins** as a highly differentiated **technology manufacturer** in **large global markets**
- seek opportunities to **move up the value chain**

DRX Revolution Nano

Our first commercial product - Healthcare

New solution in mobile X-ray for healthcare

MICRO-X

Carestream Health is a world leader in mobile X-ray for the healthcare market

- Carestream Health appointed global distributor
- Premium positioning
- **Already sold into 10 countries including U.S.**
 - Now available for sale in Australia
 - New geographies underway
- Strong customer feedback
- High reliability proven
- **\$1.25M sales in June & Sept Quarters**
- Sales expected to grow materially in Dec Quarter after Adelaide Tube approval
- **Addressable market: First Tier: \$300M, Second tier: \$200M**



Carestream trade booth – DRX Revolution Nano

Product Overview

- FDA approved Class II Medical device
- True mobile X-ray device overcoming limitations of competing mobile X-ray
- Light & manoeuvrable 90kg v 350 - 600kg
- Battery operation – 12 hour endurance
- Unique “tusks” for alignment with controls
- Bar code reader for patient-image association
- Small footprint – narrow hospital corridors/lifts
- Exceptional visibility for operator & patient safety
- **Sold as the Carestream DRX Revolution Nano**




Revised Sales & Marketing– building sales traction MICRO-X

Responding to slower than anticipated ramp up

- Early quality/yield and reliability issues – resolved with insourcing
 - Micro-X has insourced and proven a proprietary and superior emitter
 - Lack of tubes from previous supplier severely impacted Sept 2019 Quarter sales
- Sales and Marketing **strategies adapted** for breakthrough technology
 - Reset marketing approach with Carestream
- Customer head to head **demonstrations prove** technology benefits
 - Carestream have dedicated technical sales team actively running
- U.S. reference Hospitals and KOLs – **strong customer endorsement**
 - Broadens awareness and credibility for potential hospital customers
- **Australian market** now open for sales with ARTG and Quantum Health

*The sales pipeline is now growing and traction is building
– this December Quarter should see continued growth*



Manufacturing Nano units to meet demand - Tonsley, Adelaide

Insourcing & Manufacturing Scale up

MICRO-X

Next stage Expansion and vertical integration of tube supply



Capacity of 85 Nano or Rover units p.m.
Increases with weekend or second shift

Tonsley Facility, Adelaide

- > 1,000 m²
- Capacity for medium term needs
- Dedicated Rover production
- Test facilities for MBI project
- Mechanical & electrical lab space
- Shielded rooms for customer demos
- ISO 13485
- Tonsley Innovation District
– SA Government initiative



Rover mobile military x-ray


Planned sales 2020

Rover - Second Product in final development

MICRO-X

Mobile X-Ray for NATO Role 2-E Deployed Military Medical Facilities

- Currently deployable weight limits restrict choice to small-animal veterinary X-ray
- **Completed imaging tests for Australian Defence Force**
- Australian DoD negotiating with preferred tenderer for JP2060
- US Army interest strong
- **Addressable global market ~\$170M in NATO countries**
- **No competition & unmet need means higher gross margins**



Top – ADF deployed medical facility at Shoalwater Bay
Bottom – ADF demonstration at exercise Giant Viper

Product Overview

- **Based on key elements of Nano** - FDA approved Class II Medical device
- Higher energy X-ray exams used in trauma
- Light & manoeuvrable 90kg
- Hard reusable shell for military transport
- Easy battery change
- Operates on uneven surfaces
- Full performance digital imager in deployed medical facilities – War, Natural disasters
- **Sales contracts mid 2020 with first gen Rover** – delivery for customer testing after passing military risk management framework

First generation Rover – on sale mid-2020

MICRO-X

Responding to US military interest to buy the product

- **U.S. Army – Medical Materiel Agency** (medical procurement)
 - Recent demonstrations at Fort Detrick, Maryland
 - Interest for all three services - supporting deployments and domestic Base and DVA hospitals
 - Planning a Low Rate Initial Production order – **small batch of Rover without tender**
- First generation Rover will be **enhanced output & ruggedised Nano**
 - Design complete and testing underway
- Regulatory pathway - **510(k) filing early 2020** – approval mid 2020
- First sales contracts – **U.S. Army in mid-2020** – six months ahead of plan
 - Delivery for customer testing after passing military risk management framework
 - Revenue recognised on final product acceptance – by end 2020
- Australian Defence Force sales – end 2020
 - Micro-X part of successful tender for JP2060 project – completing final pricing



We aim to be selling to two major defence customers by the end of 2020 - building customer interest for larger follow-on orders

Other products in development

Mobile Backscatter Imager – Security applications

MBI - Third Product in development

MICRO-X

Unmanned assessment of potential *Improvised Explosive Devices*

- Bomb disposal technicians face life threatening harm when placing X-ray detector behind the IEDs
- MBI takes x-ray images without separate detector– **one sided**
- Australian Defence Force **proof of concept imaging completed**
- Customer support - **military and FBI / bomb disposal** interest
- **Addressable market ~\$1.8B**
- **No competition & unmet need means high gross margins**



Above – Illustration of MBI carried by EOD* Robot



Above – Current bomb disposal X-ray imaging technique

* EOD – Explosive Ordnance Disposal

Product Characteristics

- **Multi-beam CNT** imaging with **Backscatter detector** – enables one-sided X-ray image
- Thales collaborating on new tube development
- Light and able to be carried by any EOD* robot – maintaining distance of bomb technician
- Resolution of better than 0.5mm
- **Ideal in a wide range of counter-terrorism scenarios**

Future aviation security concepts

MICRO-X

Next Generation Airport X-Ray screening – ‘high speed’ and ‘self service’


High speed – Airport 3D X-ray conveyor*

- Latest ECAC Detection Standards 3 & 4
- Screen up to 1,200 bags p/h (currently 200)
- Concept uses backscatter and 3D imaging to **provide low false alarm rate**
- Automated threat detection software
- **Thales to fund development and take to market**
- Large and growing addressable market



Self service checkpoint X-ray model*

- Secondary screening at boarding gate
- **Completed Proof of Concept imaging test** for UK Government Future Airport Security Solutions
- Enables next-generation checkpoint protocols- self service for check-in and X-ray screening
- Another large and growing market



* These Programmes are subject to funding being available by the Company. MX1 has a small U.K. Govt. funded project.

Thales partnership & \$10m investment

MICRO-X

Technology partnership with a global leader in defence and aircraft security

- \$10M investment via loan facility
 - \$5m cash already received July 2019 on completion
 - Subject to EGM approval (to be sought by end 2019), Thales has option to convert loan to shares after July 2024
 - Micro-X can elect to repay loan rather than issue shares to Thales
- Contract design and licensing of Airport Checkpoint Security Imaging
- Distribution for MBI in Defence/ security - outside Five-Eyes countries
 - Australia, US, UK, Canada and New Zealand
- Contract manufacture of future miniature X-ray tubes

“....we are at the birth of a new technology evolution. CNT is a game changer in so many fields but none offer such practical and quantifiable benefits as in the X-ray imaging market. From airport checkpoints to counter terrorism activities to future medical imaging devices, Thales and Micro-X are at the cusp of an historical moment. This partnership will give us a technological leap that no one else in this industry has.”

Jean Jacques Guittard, Thales Vice-President, Electron Devices

Goals & Objectives

We are now setting course

Milestones - setting our new course

MICRO-X

Focused on delivering commercial outcomes for all stakeholders

CY 2019

Early US sales of Nano
Thales Partnering deal & \$5m
Next Stage Facility expansion
CNT in-sourcing complete
First Nano sales with MX1 tube
Patent published - CNT emitter
Reference hospitals + KOLs
UK Airport security grant award

Q4 – Build sales + pipeline
Q4 – Nano sold in Australia
Q4 – Japan entry strategy
Q4 – Rover tube built & tested

CY 2020

1H – Rover 1st gen 510(k)
1H - Building Nano sales
1H – Japanese reg process
2H – Rover 1st gen U.S. Army sales
2H – MBI first imaging demo
2H – Rover 2nd gen 510(k)
2H – Rover 2nd gen ADF contract

Beyond

Significant Rover & Nano sales
Japan reg clearance – Nano
MBI customer demo / testing
MBI launch in ~ 2022
Airport security prototype

The above forecast dates are estimated and indicative and may change

Conclusions

MICRO-X

Building commercialisation of next generation X-ray technology

- **Next generation** X-ray platform – health and security markets
- Significant **technology advantages**
 - smaller, lighter, more mobility, new applications
- Strategy and **focus on technology development** & manufacture
- Commercial **sales via partnerships** with **global leaders**
 - Carestream (Healthcare) + Thales (Security & defence)
- First product in sales and now growing + **second product in sales < 12 months**
 - New products in **larger markets** with **increased financial returns**





MICRO-X

ACN 153 273 735

Peter Rowland

Managing Director

1284 South Road
Tonsley SA 5042

+61 8 7099 3966

admin@micro-x.com